Mochi Review (2026): Built Around Ongoing Care
Last updated: March 2026 Disclosure: This page contains affiliate links. We may earn a commission if you enroll through a link. All recommendations are independently made. Compounded medications are not FDA-approved and are regulated differently from brand-name drugs. Instant Dec
Last updated: March 2026
Disclosure: This page contains affiliate links. We may earn a commission if you enroll through a link. All recommendations are independently made. Compounded medications are not FDA-approved and are regulated differently from brand-name drugs.
The FDA has proposed excluding semaglutide and liraglutide from the 503B bulk compounding list, with public comments open through June 29, 2026. If finalized, this could affect the availability, pricing, and continuity of some compounded GLP-1 programs. We will update this page as the regulatory situation develops.
Instant Decision Summary
- Best for: Ongoing support and flexibility
- Entry pricing: Low — but total cost rises with medication
- Medication: Compounded semaglutide; flexible options
- Support level: High — coaching and continuous access
- Best alternative: Henry Meds for simpler bundled pricing
Where Mochi Stands Out
Mochi is structured around continuous support. This is where it differentiates immediately — you are not just getting a prescription, you are getting a system with coaching and flexibility built in.
Where Mochi Falls Short
Costs layer quickly once medication is added. The headline price is not the full picture. This is where many users underestimate their total monthly spend.
Who This Is For
- Users who want coaching and ongoing clinical access
- Users who want flexibility in medication options
- Users who value continuous support throughout treatment
Who Should Avoid Mochi
- Users who want total cost certainty upfront
- Users who want the fastest, simplest onboarding
- Users on a strict budget who cannot absorb variable medication costs